ASH 2018 | CLL updates from ASH 2018: ibrutinib is the treatment of choice

John Gribben

John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of the Barts Cancer Institute, London, UK, provides an overview of key updates in treatment for chronic lymphocytic leukemia (CLL), specifically the ECOG-E1912 (NCT02048813), MURANO (NCT02005471), and iLLUMINATE (NCT02264574) studies investigating ibrutinib alone or in combination with monoclonal antibodies vs. FCR – the standard chemoimmunotherapy treatment. Prof. Gribben was speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video